#startup of the day 20 - Guttify

August 31, 2026 | Monday | Features

Reimagining gut health through personalised nutrition

Inception - 2023

Location - Gurugram, Haryana, India

Industry domain -  HealthTech / Consumer Health / Gut Health & Diagnostics

Founders - Mukul Shah and Mansi Sharma

Total Team Strength - 50-55

Total funds raised -  Over ₹10.25 crore cumulatively to date, including a ₹4 crore follow-on round in February 2026 .

Investors - Guttify’s investor base includes the family office associated with the Unichem Laboratories family office, Expert Dojo, Agility Ventures, Sunn91 Ventures, government-backed seed programmes, and prominent angel investors including Nitish Mittersain (Nazara Technologies) and Ahana Gautam (Open Secret).


Revenue Generated Since Inception - Business growth metrics: 67% QoQ growth, ~20% monthly user growth and a 40% repeat-user rate.

Current Valuation - Approximately ₹54 crore, based on available reports.

Key Highlights -

  1. Raised a $360,000 extended seed round in May 2025. • Raised a further ₹4 crore follow-on round in February 2026. 
  2. Crossed 30,000 users for its ₹399 DIY Gut Scan Kit.
  3. Recorded 67% quarter-on-quarter growth and approximately 20% monthly user growth. 
  4. Built a 40% repeat-user rate, indicating growing consumer engagement. 
  5. Expanded its positioning from gut-health awareness towards a broader diagnosis-first consumer health platform

Target Fundraise - Having raised over ₹10 crore cumulatively, Guttify is now targeting a ₹20 crore fundraise to strengthen its diagnostic capabilities, expand its product portfolio and deepen its presence across Tier 1 and Tier 2 cities.

Purpose of fundraising - Scaling diagnostic capabilities, technology, product innovation and geographical expansion, particularly across Tier 1 and Tier 2 markets.

Founder Speaks - 

Guttify is planning to raise around ₹20 crore to scale its diagnostic capabilities, strengthen technology and accelerate product innovation. The company plans to expand its presence across Tier 1 and Tier 2 cities and broaden its product portfolio across areas such as bloating, digestion and liver health.

- Mukul Shah 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

OR

Forgot your password?

OR

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy